Stock comparison
DexCom
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DXCM
DexCom
Market cap
$27.82B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DXCM | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 77B | LMAT |
| Benjamin Graham | 74B | 89A | LMAT |
| Philip Fisher | 75B | 81C | LMAT |
| Peter Lynch | 61C | 67B | LMAT |
| Joel Greenblatt | 58C | 56D | DXCM |
| Charlie Munger | 66B | 68D | LMAT |
| Terry Smith | 66B | 69D | LMAT |
Side-by-side metrics
| Metric | DXCM | LMAT |
|---|---|---|
| Market cap | $27.82B | $2.23B |
| P/E (TTM) | 24.6x | 37.1x |
| EV/EBIT | 25.4x | 36.6x |
| ROIC (TTM) | 18.03% | 9.43% |
| Gross margin | 61.84% | 72.39% |
| Net margin | 19.31% | 24.35% |
| Revenue CAGR 5y | 17.47% | 12.75% |
| EPS CAGR 5y | 39.82% | 19.04% |
| Debt / Equity | 0.5x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DXCM leads on
- Market cap$27.82Bvs $2.23B+92%
- EPS CAGR 5y39.82%vs 19.04%+52%
- ROIC (TTM)18.03%vs 9.43%+48%
- P/E (TTM)24.6xvs 37.1x+34%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 19.31%+21%
- Gross margin72.39%vs 61.84%+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.